We are analyzing https://link.springer.com/article/10.1007/s10434-001-0580-9.

Title:
Patient Reluctance Toward Tamoxifen Use for Breast Cancer Primary Prevention | Annals of Surgical Oncology
Description:
Background: The National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 trial demonstrated that tamoxifen reduces the incidence of new breast cancers by 49% in women at increased risk for breast cancer development. Tamoxifen does have side effects, however, including marginally increased risks of endometrial cancer and thromboembolic events. In this study, women at increased risk for breast cancer development were offered tamoxifen. Their knowledge of tamoxifen as a chemopreventive agent was assessed, and factors influencing their acceptance of tamoxifen and willingness to take it were determined. Methods: Forty-three patients were identified who qualified to take tamoxifen for primary prevention. Patients qualified by having at least a 1.7% 5-year risk of developing breast cancer, the criteria for entry into the NSABP P-1 trial. Patients initially completed questionnaires designed to assess their knowledge of tamoxifen and its associated risks and benefits. Patients were then provided neutral educational sessions and literature delineating the actual risks and benefits of tamoxifen. Subsequently, patients’ decisions regarding taking tamoxifen were reassessed. Results: Mean patient age was 52.8 years, with a range of 39 to 74 years. Ten patients (23.2%) qualified based on the presence of lobular carcinoma in situ (LCIS), seven patients (16.3%) qualified based on increased risk secondary to age >60 years, and 26 patients (60.5%) age range 35 to 59 qualified based on risk profiles demonstrating significantly increased risk. Of the total 43 patients, two (4.7%) elected to start taking tamoxifen. Fifteen patients (34.8%) declined immediately, and 26 patients (60.5%) were undecided initially but ultimately declined. Educational sessions did not influence patients’ decisions. Fear of side effects, including endometrial cancer, thromboembolic events, and menopausal symptoms, was the most commonly cited reason for declining to take tamoxifen. Conclusions: In this study, the vast majority of patients at increased risk for breast cancer perceived that the risks of taking tamoxifen outweighed the benefits and declined to take it.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Insurance
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

cancer, breast, tamoxifen, google, scholar, patients, article, cas, risk, pubmed, prevention, increased, patient, women, access, privacy, cookies, content, trial, risks, study, qualified, publish, search, surgical, reluctance, port, benefits, age, therapy, lancet, york, analysis, data, including, information, log, journal, research, primary, elisa, rush, montgomery, heerdt, adjuvant, endometrial, taking, results, years, based,

Topics {✒️}

month download article/chapter predicted anti-oestrogen resistance early breast cancer related subjects full article pdf privacy choices/manage cookies surgical oncology aims breast cancer development developing breast cancer breast cancer perceived preventing breast cancer contralateral breast cancer including endometrial cancer p-1 trial demonstrated endometrial cancer risk article port increased risk secondary familial breast cancers european economic area commonly cited reason multicentre prospective survey gail mh brca2 mutation carriers case-control study modifying compliance behavior nsabp p-1 trial italian randomized trial risk-reducing medication conditions privacy policy article annals check access instant access accepting optional cookies niddm patients’ fears breast cancer primary prevention taking tamoxifen outweighed start taking tamoxifen literature delineating promoting treatment acceptance patient reluctance influence patients’ decisions article log journal finder publish endometrial cancer brca1/2-positive women article cite increased risk breast cancers cancer statistics

Questions {❓}

How do patients’ views about medication affect their self-management in asthma?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Patient Reluctance Toward Tamoxifen Use for Breast Cancer Primary Prevention
         description: Background: The National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 trial demonstrated that tamoxifen reduces the incidence of new breast cancers by 49% in women at increased risk for breast cancer development. Tamoxifen does have side effects, however, including marginally increased risks of endometrial cancer and thromboembolic events. In this study, women at increased risk for breast cancer development were offered tamoxifen. Their knowledge of tamoxifen as a chemopreventive agent was assessed, and factors influencing their acceptance of tamoxifen and willingness to take it were determined. Methods: Forty-three patients were identified who qualified to take tamoxifen for primary prevention. Patients qualified by having at least a 1.7% 5-year risk of developing breast cancer, the criteria for entry into the NSABP P-1 trial. Patients initially completed questionnaires designed to assess their knowledge of tamoxifen and its associated risks and benefits. Patients were then provided neutral educational sessions and literature delineating the actual risks and benefits of tamoxifen. Subsequently, patients’ decisions regarding taking tamoxifen were reassessed. Results: Mean patient age was 52.8 years, with a range of 39 to 74 years. Ten patients (23.2%) qualified based on the presence of lobular carcinoma in situ (LCIS), seven patients (16.3%) qualified based on increased risk secondary to age >60 years, and 26 patients (60.5%) age range 35 to 59 qualified based on risk profiles demonstrating significantly increased risk. Of the total 43 patients, two (4.7%) elected to start taking tamoxifen. Fifteen patients (34.8%) declined immediately, and 26 patients (60.5%) were undecided initially but ultimately declined. Educational sessions did not influence patients’ decisions. Fear of side effects, including endometrial cancer, thromboembolic events, and menopausal symptoms, was the most commonly cited reason for declining to take tamoxifen. Conclusions: In this study, the vast majority of patients at increased risk for breast cancer perceived that the risks of taking tamoxifen outweighed the benefits and declined to take it.
         datePublished:
         dateModified:
         pageStart:580
         pageEnd:585
         sameAs:https://doi.org/10.1007/s10434-001-0580-9
         keywords:
            Tamoxifen
            Breast cancer
            Chemoprevention
            Patient reluctance
            Surgical Oncology
            Oncology
            Surgery
         image:
         isPartOf:
            name:Annals of Surgical Oncology
            issn:
               1534-4681
               1068-9265
            volumeNumber:8
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Elisa Rush Port
               affiliation:
                     name:Memorial Sloan-Kettering Cancer Center
                     address:
                        name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
                        type:PostalAddress
                     type:Organization
                     name:Memorial Sloan-Kettering Cancer Center
                     address:
                        name:Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Leslie L. Montgomery
               affiliation:
                     name:Memorial Sloan-Kettering Cancer Center
                     address:
                        name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Alexandra S. Heerdt
               affiliation:
                     name:Memorial Sloan-Kettering Cancer Center
                     address:
                        name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Patrick I. Borgen
               affiliation:
                     name:Memorial Sloan-Kettering Cancer Center
                     address:
                        name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Patient Reluctance Toward Tamoxifen Use for Breast Cancer Primary Prevention
      description: Background: The National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 trial demonstrated that tamoxifen reduces the incidence of new breast cancers by 49% in women at increased risk for breast cancer development. Tamoxifen does have side effects, however, including marginally increased risks of endometrial cancer and thromboembolic events. In this study, women at increased risk for breast cancer development were offered tamoxifen. Their knowledge of tamoxifen as a chemopreventive agent was assessed, and factors influencing their acceptance of tamoxifen and willingness to take it were determined. Methods: Forty-three patients were identified who qualified to take tamoxifen for primary prevention. Patients qualified by having at least a 1.7% 5-year risk of developing breast cancer, the criteria for entry into the NSABP P-1 trial. Patients initially completed questionnaires designed to assess their knowledge of tamoxifen and its associated risks and benefits. Patients were then provided neutral educational sessions and literature delineating the actual risks and benefits of tamoxifen. Subsequently, patients’ decisions regarding taking tamoxifen were reassessed. Results: Mean patient age was 52.8 years, with a range of 39 to 74 years. Ten patients (23.2%) qualified based on the presence of lobular carcinoma in situ (LCIS), seven patients (16.3%) qualified based on increased risk secondary to age >60 years, and 26 patients (60.5%) age range 35 to 59 qualified based on risk profiles demonstrating significantly increased risk. Of the total 43 patients, two (4.7%) elected to start taking tamoxifen. Fifteen patients (34.8%) declined immediately, and 26 patients (60.5%) were undecided initially but ultimately declined. Educational sessions did not influence patients’ decisions. Fear of side effects, including endometrial cancer, thromboembolic events, and menopausal symptoms, was the most commonly cited reason for declining to take tamoxifen. Conclusions: In this study, the vast majority of patients at increased risk for breast cancer perceived that the risks of taking tamoxifen outweighed the benefits and declined to take it.
      datePublished:
      dateModified:
      pageStart:580
      pageEnd:585
      sameAs:https://doi.org/10.1007/s10434-001-0580-9
      keywords:
         Tamoxifen
         Breast cancer
         Chemoprevention
         Patient reluctance
         Surgical Oncology
         Oncology
         Surgery
      image:
      isPartOf:
         name:Annals of Surgical Oncology
         issn:
            1534-4681
            1068-9265
         volumeNumber:8
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Elisa Rush Port
            affiliation:
                  name:Memorial Sloan-Kettering Cancer Center
                  address:
                     name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
                     type:PostalAddress
                  type:Organization
                  name:Memorial Sloan-Kettering Cancer Center
                  address:
                     name:Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Leslie L. Montgomery
            affiliation:
                  name:Memorial Sloan-Kettering Cancer Center
                  address:
                     name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Alexandra S. Heerdt
            affiliation:
                  name:Memorial Sloan-Kettering Cancer Center
                  address:
                     name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Patrick I. Borgen
            affiliation:
                  name:Memorial Sloan-Kettering Cancer Center
                  address:
                     name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Annals of Surgical Oncology
      issn:
         1534-4681
         1068-9265
      volumeNumber:8
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Memorial Sloan-Kettering Cancer Center
      address:
         name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
         type:PostalAddress
      name:Memorial Sloan-Kettering Cancer Center
      address:
         name:Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York
         type:PostalAddress
      name:Memorial Sloan-Kettering Cancer Center
      address:
         name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
         type:PostalAddress
      name:Memorial Sloan-Kettering Cancer Center
      address:
         name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
         type:PostalAddress
      name:Memorial Sloan-Kettering Cancer Center
      address:
         name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Elisa Rush Port
      affiliation:
            name:Memorial Sloan-Kettering Cancer Center
            address:
               name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
               type:PostalAddress
            type:Organization
            name:Memorial Sloan-Kettering Cancer Center
            address:
               name:Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York
               type:PostalAddress
            type:Organization
      name:Leslie L. Montgomery
      affiliation:
            name:Memorial Sloan-Kettering Cancer Center
            address:
               name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
               type:PostalAddress
            type:Organization
      name:Alexandra S. Heerdt
      affiliation:
            name:Memorial Sloan-Kettering Cancer Center
            address:
               name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
               type:PostalAddress
            type:Organization
      name:Patrick I. Borgen
      affiliation:
            name:Memorial Sloan-Kettering Cancer Center
            address:
               name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
      name:Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York
      name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
      name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
      name:Breast Service, Memorial Sloan-Kettering Cancer Center, New York
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(66)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.01s.

LINK . SPRINGER . COM {}